Company / Cash & Equivalents
Astria Therapeutics, Inc. Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$59.8M
FY2024
5-year range
$20.5M / $175.5M
FY2020-FY2024
Trend
-65.9%
vs FY2023
Sector context
#175 of 207
Health Care
What the data says
Astria Therapeutics, Inc.'s cash & equivalents of $60M is lower than 85% of companies in the Health Care sector (FY2024). Cash & Equivalents has fluctuated over the past 10 years, ranging from $10M in FY2019 to $176M in FY2023.
Based on SEC 10-K filings.
$60M in FY2024 with a 5-year CAGR of +43.3%.
Improved from $21M to $60M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -11.6%
- 5-Year CAGR
- +43.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 207This company $59.8M Sector average $669.5M
▼
-91.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +43.3%, indicating consistent growth.
- In FY2024, cash & equivalents decreased 65.9% year-over-year.
- Ranks #175 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $59.8M | -65.9% |
| FY2023 | $175.5M | +755.2% |
| FY2022 | $20.5M | -76.3% |
| FY2021 | $86.5M | +247.0% |
| FY2020 | $24.9M | +151.8% |
| FY2019 | $9.9M | -35.3% |
| FY2018 | $15.3M | -6.6% |
| FY2017 | $16.4M | -30.6% |
| FY2016 | $23.6M | -62.4% |
| FY2015 | $62.8M | +328.0% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026